Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid + Rituximab in Indolent NHL
NCT00695786Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2008
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00695786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00695786.